Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03519672 · ClinicalTrials.gov registry record
Prospective Psychometric Evaluation Study of a Patient-reported Outcomes (PRO) Instrument for Congenital Thrombotic Thrombocytopenic Purpura (cTTP, Upshaw-Schulman Syndrome [USS], Hereditary Thrombotic Thrombocytopenic Purpura [hTTP]
A clinical trial, sponsored by Baxalta now part of Shire.
- Completed
- Registry status
- 41
- Enrollment target
NCT03519672 is a clinical trial that has completed, run by Baxalta now part of Shire. The registered enrollment target is 41 participants.
The verdict
NCT03519672 has completed, sponsored by Baxalta now part of Shire.
- COMPLETED
- Registry status
- 41 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the psychometric properties of a recently developed congenital thrombotic thrombocytopenic purpura (cTTP)-specific patient-reported outcomes (PRO) instrument.
Interventions
- OTHER No intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2018-07-12 |
| Est. Completion | 2019-04-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03519672
The ClinicalTrials.gov registry entry for NCT03519672 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baxalta now part of Shire, which has 74 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which No intervention is the first listed.
NCT03519672 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03519672 about?
NCT03519672 is a clinical study titled "Prospective Psychometric Evaluation Study of a Patient-reported Outcomes (PRO) Instrument for Congenital Thrombotic Thrombocytopenic Purpura (cTTP, Upshaw-Schulman Syndrome [USS], Hereditary Thrombotic Thrombocytopenic Purpura [hTTP]". The purpose of this study is to assess the psychometric properties of a recently developed congenital thrombotic thrombocytopenic purpura (cTTP)-specific patient-reported outcomes (PRO) instrument.
What is the current status of trial NCT03519672?
This trial is currently completed. The enrollment target is 41 participants. The study started on 2018-07-12. Estimated completion is 2019-04-08.
What interventions are being tested in trial NCT03519672?
The interventions under investigation include: No intervention (OTHER).
Who is sponsoring clinical trial NCT03519672?
This trial is sponsored by Baxalta now part of Shire, which has 74 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.